Comparative Pharmacology
Head-to-head clinical analysis: ENSKYCE versus MIRCETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSKYCE versus MIRCETTE.
ENSKYCE vs MIRCETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
None Documented
None Documented
12 hours (terminal); allows once-daily dosing in most patients
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Category C
Category C
Oral Contraceptive
Oral Contraceptive